收藏切换
Application and discussion of patient-reported outcome measures in rare diseases clinical research
收藏切换
Lin ZHU1, Jiahao HU1, Qi KANG1, Yifan XU2, Chunlin JIN1, *
World Clinical Drug | 2022, 43(2) : 124 - 129
Less
收藏切换
World Clinical Drug | 2022, 43(2): 124-129
• Topic •
Application and discussion of patient-reported outcome measures in rare diseases clinical research
Full
Lin ZHU1, Jiahao HU1, Qi KANG1, Yifan XU2, Chunlin JIN1, *
Affiliations
  • 1.Shanghai Health Development Research Center, Shanghai 200040, China
  • 2.Shanghai University of Traditional Chinese Medicine, School of Public Health, Shanghai 201203, China
Published: 2022-02-10 doi: 10.13683/j.wph.2022.02.003
Outline
收藏切换

Patient-reported outcomes (PROs) refers to reports directly obtained from patients about their health status, physical function and treatment experience, which has been widely used in evaluation of quality of life in chronic diseases, clinical trials, adverse event monitoring and drug registration and approval in recent years. Rare diseases are a kind of diseases that seriously affect the physical function, mental health and quality of life of patients. Due to the lack of understanding of the natural history of rare diseases and the lack of sensitive biomarkers, patients' opinions and feelings are the key and ultimate goal of clinical decision making and intervention efficacy evaluation for rare diseases. At present, domestic research on PROs is just starting, and few involves in rare diseases. Therefore, this article reviewed the international definition, policy history and application status of PRO in rare diseases, and further discussed the existing challenges in the application of PRO in rare diseases, and looked forward to the application prospects of PRO in China.

patient-reported outcome  /  rare disease  /  efficacy evaluation  /  clinical research
朱琳, 胡嘉浩, 康琦, 许艺帆, 金春林. 患者报告结局在罕见病临床研究中的应用探讨. 世界临床药物, 2022 , 43 (2) : 124 -129 . DOI: 10.13683/j.wph.2022.02.003
Lin ZHU, Jiahao HU, Qi KANG, Yifan XU, Chunlin JIN. Application and discussion of patient-reported outcome measures in rare diseases clinical research[J]. World Clinical Drug, 2022 , 43 (2) : 124 -129 . DOI: 10.13683/j.wph.2022.02.003
Year 2022 volume 43 Issue 2
18
6
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.02.003
  • Receive Date:2021-11-18
  • Online Date:2026-11-19
  • Published:2022-02-10
Article Data
Affiliations
History
  • Received:2021-11-18
  • Revised:2022-01-18
Funding
Affiliations
    1.Shanghai Health Development Research Center, Shanghai 200040, China
    2.Shanghai University of Traditional Chinese Medicine, School of Public Health, Shanghai 201203, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.02.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT